Table 2.

Change in the distribution and reductions in cCMV infection by type of maternal infection, 10, 20 and 50 years after introduction of vaccine, assuming mixing pattern III, age-specific duration of infectiousness, 20 year duration of latency, 90% vaccine coverage, 70% vaccine efficacy, 5-year duration of vaccine protection, and different ages at vaccination, United States and Brazil.

Setting	Age at vaccination	Type of maternal infection	Distribution (%) of cCMV infections by type of maternal infection				Reduction (%) in cCMV infections by type of maternal infection
			Pre- Vaccination (Baseline)	Years Post-Vaccination			Years Post-Vaccination
				10	20	50	10	20	50
United States	12-18 months	Primary	16	12	14	20	39	35	21
		Reinfection	12	8	8	7	43	50	62
		Reactivation	72	80	79	72	4	13	35
		Overall	100				14	21	36
	15-19 years	Primary	16	16	17	17	18	16	14
		Reinfection	12	12	12	11	17	19	21
		Reactivation	72	72	72	71	15	17	19
		Overall	100				16	17	18
	12-18 months +	Primary	16	11	14	22	49	44	29
		Reinfection	12	8	7	7	53	58	69
	15-19 years	Reactivation	72	81	79	72	17	25	45
		Overall	100				27	32	45
	20-29 years	Primary	16	18	18	18	27	24	23
		Reinfection	12	12	12	12	32	32	32
		Reactivation	72	71	70	70	32	32	32
		Overall	100				31	30	31
	12-18 months	Primary	15	13	20	25	32	1	−24
Brazil		Reinfection	38	28	27	27	46	49	48
		Reactivation	47	59	53	48	5	17	24
		Overall	100				25	27	26
	15-19 years	Primary	15	15	16	16	31	26	24
		Reinfection	38	38	37	37	34	34	35
		Reactivation	47	48	47	47	30	32	32
		Overall	100				32	32	32
	12-18 months +	Primary	15	13	22	29	53	23	−3
		Reinfection	38	27	25	25	64	66	66
	15-19 years	Reactivation	47	60	53	47	32	41	47
		Overall	100				48	48	47

Footnote: Results for age at vaccination of 20-29 years not shown for Brazil because this scenario would lead to the least reduction in cCMV infections.